Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Mechanism based representation of the active site of 5 alpha-reductase (5AR).

Ahmed S, Denison S.

Bioorg Med Chem Lett. 1998 Sep 22;8(18):2615-70.

PMID:
9873591
3.

The enzyme and inhibitors of 4-ene-3-oxosteroid 5 alpha-oxidoreductase.

Li X, Chen C, Singh SM, Labrie F, Labire F [corrected to Labrie F].

Steroids. 1995 Jun;60(6):430-41. Review. Erratum in: Steroids 1995 Aug;60(8):540.

PMID:
7676475
4.

Structure activity relationship study of known inhibitors of the enzyme 5 alpha-reductase (5AR).

Ahmed S, Denison S.

Bioorg Med Chem Lett. 1998 Mar 3;8(5):409-14.

PMID:
9871588
6.
7.

Substrate interaction with 5alpha-reductase enzyme: influence of the 17beta-chain chirality in the mechanism of action of 4-azasteroid inhibitors.

Grisenti P, Magni A, Olgiati V, Manzocchi A, Ferraboschi P, Villani V, Pucciariello R, Celotti F.

Steroids. 2001 Nov;66(11):803-10.

PMID:
11576619
8.

A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.

Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO.

Clin Pharmacol Ther. 1998 Dec;64(6):636-47.

PMID:
9871428
9.

Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.

Frye SV, Haffner CD, Maloney PR, Hiner RN, Dorsey GF, Noe RA, Unwalla RJ, Batchelor KW, Bramson HN, Stuart JD, et al.

J Med Chem. 1995 Jul 7;38(14):2621-7.

PMID:
7629802
10.

Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.

Makridakis N, Reichardt JK.

J Mol Endocrinol. 2005 Jun;34(3):617-23.

PMID:
15956333
11.
12.

Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.

Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.

Clin Cancer Res. 2006 Jul 1;12(13):4072-9.

PMID:
16818707
13.

Self-organizing molecular field analysis on pregnane derivatives as human steroidal 5alpha-reductase inhibitors.

Aggarwal S, Thareja S, Bhardwaj TR, Kumar M.

Steroids. 2010 Jun;75(6):411-8. doi: 10.1016/j.steroids.2010.02.005.

PMID:
20170668
14.

6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.

Frye SV, Haffner CD, Maloney PR, Mook RA Jr, Dorsey GF Jr, Hiner RN, Cribbs CM, Wheeler TN, Ray JA, Andrews RC, et al.

J Med Chem. 1994 Jul 22;37(15):2352-60.

PMID:
8057283
15.
16.

5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.

Cabeza M, Quiroz A, Bratoeff E, García G, Ramírez E, Flores E.

Proc West Pharmacol Soc. 2002;45:164-5.

PMID:
12434569
17.

Inhibition of rat steroid 5 alpha-reductase (isozyme 1) by suramin.

Taylor MF, Bhattacharyya AK, Collins DC.

Steroids. 1995 Jul;60(7):452-6.

PMID:
7482629
18.

Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism.

Moss ML, Kuzmic P, Stuart JD, Tian G, Peranteau AG, Frye SV, Kadwell SH, Kost TA, Overton LK, Patel IR.

Biochemistry. 1996 Mar 19;35(11):3457-64.

PMID:
8639496
19.

A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia.

Sun ZY, Tu ZH.

Methods Find Exp Clin Pharmacol. 1998 May;20(4):283-7.

PMID:
9658376
20.
Items per page

Supplemental Content

Support Center